Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release

Bibliography

• Beasley CM Jr, Hamilton SH, Crawford AM, et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 1997;7(2):125-37
   PubMed Web of Science ®Google Scholar
• Daniel DG, Zimbroff DL, Potkin SG, et al. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 1999;20(5):491-505
   PubMed Web of Science ®Google Scholar
• Emsley RA, Raniwalla J, Bailey PJ, et al. A comparison of the effects of quetiapine (‘seroquel’) and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group. Int Clin Psychopharmacol 2000;15(3):121-31
   PubMed Web of Science ®Google Scholar
• Kasper S. First-episode schizophrenia: the importance of early intervention and subjective tolerability. J Clin Psychiatry 1999;60(Suppl 23):5-9
   Google Scholar
• Lindenmayer JP, Grochowski S, Mabugat L. Clozapine effects on positive and negative symptoms: a six-month trial in treatment-refractory schizophrenics. J Clin Psychopharmacol 1994;14(3):201-4
   PubMed Web of Science ®Google Scholar
• Lindström E, Eriksson B, Hellgren A, et al. Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia. Clin Ther 1995;17(3):402-12
   PubMed Web of Science ®Google Scholar
• Bilder RM, Goldman RS, Volavka J, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002;159(6):1018-28
   PubMed Web of Science ®Google Scholar
• Lublin H, Eberhard J, Levander S. Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics. Int Clin Psychopharmacol 2005;20(4):183-98
   PubMed Web of Science ®Google Scholar
• Csernansky JG, Schuchart EK. Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics. CNS Drugs 2002;16(7):473-84
   PubMed Web of Science ®Google Scholar
• Leucht S, Barnes TR, Kissling W, et al. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003;160(7):1209-22
   PubMed Web of Science ®Google Scholar
• Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60(6):553-64
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Mcgurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999;25(2):233-55
   PubMed Web of Science ®Google Scholar
• Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004;161(3):414-25
   PubMed Web of Science ®Google Scholar
• Gerlach J. The continuing problem of extrapyramidal symptoms: strategies for avoidance and effective treatment. J Clin Psychiatry 1999;60(Suppl 23):20-4
   Google Scholar
• Leucht S, Pitschel-Walz G, Abraham D, et al. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 1999;35(1):51-68
   PubMed Web of Science ®Google Scholar
• Kane JM, Barrett EJ, Casey DE, et al. Metabolic effects of treatment with atypical antipsychotics. J Clin Psychiatry 2004;65(11):1447-55
   PubMed Web of Science ®Google Scholar
• Nasrallah HA, Newcomer JW. Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol 2004;24 (Suppl 1):S7-14
   Google Scholar
• Newcomer JW. Abnormalities of glucose metabolism associated with atypical antipsychotic drugs. J Clin Psychiatry 2004;65 (Suppl 18):36-46
   Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353(12):1209-23
   PubMed Web of Science ®Google Scholar
• Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry 2007;164(3):415-27
   PubMed Web of Science ®Google Scholar
• Pani L, Pira L, Marchese G. Antipsychotic efficacy: relationship to optimal D2-receptor occupancy. Eur Psychiatry 2007;22(5):267-75
   PubMed Web of Science ®Google Scholar
• Karlsson P, Dencker E, Nyberg S, et al. Pharmacokinetic and dopamine D2 and serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects. Eur Neuropsychopharmacol 2005;15 (Suppl 3):S385
   Web of Science ®Google Scholar
• WHO Drug Information 2006;20(2):100
   Google Scholar
• Emsley R, Berwaerts J, Eerdekens M, et al. Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies. Int Clin Psychopharmacol 2008;23(6):343-56
   PubMed Web of Science ®Google Scholar
• Kramer M, Simpson G, Maciulis V, et al. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2007;27(1):6-14
   PubMed Web of Science ®Google Scholar
• Davidson M, Emsley R, Kramer M, et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res 2007;93(1-3):117-30
   PubMed Web of Science ®Google Scholar
• Kane J, Canas F, Kramer M, et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 2007;90(1-3):147-61
   PubMed Web of Science ®Google Scholar
• Marder SR, Kramer M, Ford L, et al. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry 2007;62(12):1363-70
   PubMed Web of Science ®Google Scholar
• Tessier C, Nuss P, Staneva G, et al. Modification of membrane heterogeneity by antipsychotic drugs: an X-ray diffraction comparative study. J Colloid Interface Sci 2008;320(2):469-75
   PubMed Web of Science ®Google Scholar
• Jutila A, Söderlund T, Pakkanen AL, et al. Comparison of the effects of clozapine, chlorpromazine, and haloperidol on membrane lateral heterogeneity. Chem Phys Lipids 2001;112(2):151-63
   PubMed Web of Science ®Google Scholar
• Leysen JE, Janssen PM, Schotte A, et al. Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors. Psychopharmacology (Berl) 1993;112(1 Suppl):S40-54
   Google Scholar
• Schotte A, Bonaventure P, Janssen PF, et al. In vitro receptor binding and in vivo receptor occupancy in rat and guinea pig brain: risperidone compared with antipsychotics hitherto used. Jpn J Pharmacol 1995;69(4):399-412
   PubMedGoogle Scholar
• Schotte A, Janssen PF, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 1996;124(1-2):57-73
   PubMed Web of Science ®Google Scholar
• Riedel M, Schwarz MJ, Strassnig M, et al. Risperidone plasma levels, clinical response and side-effects. Eur Arch Psychiatry Clin Neurosci 2005;255(4):261-8
   PubMed Web of Science ®Google Scholar
• Dremencov E, El Mansari M, Blier P. Distinct electrophysiological effects of paliperidone and risperidone on the firing activity of rat serotonin and norepinephrine neurons. Psychopharmacology (Berl) 2007;194(1):63-72
   PubMed Web of Science ®Google Scholar
• Zhu HJ, Wang JS, Markowitz JS, et al. Risperidone and paliperidone inhibit p-glycoprotein activity in vitro. Neuropsychopharmacology 2007;32(4):757-64
   PubMed Web of Science ®Google Scholar
• Ambudkar SV, Dey S, Hrycyna CA, et al. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999;39:361-98
   PubMed Web of Science ®Google Scholar
• Uhr M, Tontsch A, Namendorf C, et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 2008 24;57(2):203-9
   Google Scholar
• Leschziner GD, Andrew T, Pirmohamed M, et al. ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J 2007;7(3):154-79
   PubMed Web of Science ®Google Scholar
• Kirschbaum KM, Henken S, Hiemke C, et al. Pharmacodynamic consequences of P-glycoprotein-dependent pharmacokinetics of risperidone and haloperidol in mice. Behav Brain Res 2008;188(2):298-303
   PubMed Web of Science ®Google Scholar
• Xing Q, Gao R, Li H, et al. Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients. Pharmacogenomics 2006;7:987-93
   PubMed Web of Science ®Google Scholar
• Wang JS, Zhu HJ, Markowitz JS, et al. Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl) 2006;187(4):415-23
   PubMed Web of Science ®Google Scholar
• Nakagami T, Yasui-furukori N, Saito M, et al. Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition. Clin Pharmacol Ther 2005;78(1):43-51
   PubMed Web of Science ®Google Scholar
• Vermeir M, Naessens I, Remmerie B, et al. Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. Drug Metab Dispos 2008;36(4):769-79
   PubMed Web of Science ®Google Scholar
• Haefeli WE, Bargetzi MJ, Follath F, et al. Potent inhibition of cytochrome P450IID6 (debrisoquin 4-hydroxylase) by flecainide in vitro and in vivo. J Cardiovasc Pharmacol 1990;15(5):776-9
   PubMed Web of Science ®Google Scholar
• Prior TI, Baker GB. Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci 2003;28(2):99-112
   PubMed Web of Science ®Google Scholar
• Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol 2007;100(1):4-22
   PubMed Web of Science ®Google Scholar
• Spina E, Avenoso A, Facciolà G, et al. Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine. Ther Drug Monit 2001;23(3):223-7
   PubMed Web of Science ®Google Scholar
• Spina E, Avenoso A, Scordo MG, et al. Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. J Clin Psychopharmacol 2002;22(4):419-23
   PubMed Web of Science ®Google Scholar
• Bondolfi G, Eap CB, Bertschy G, et al. The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. Pharmacopsychiatry 2002;35(2):50-6
   PubMed Web of Science ®Google Scholar
• Ono S, Mihara K, Suzuki A, et al. Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes. Psychopharmacology (Berl) 2002;162(1):50-4
   PubMed Web of Science ®Google Scholar
• Scordo MG, Spina E, Facciolà G, et al. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl) 1999;147(3):300-5
   PubMed Web of Science ®Google Scholar
• Van Schaick EA, Lechat P, Remmerie BM, et al. Pharmacokinetic comparison of fast-disintegrating and conventional tablet formulations of risperidone in healthy volunteers. Clin Ther 2003;25(6):1687-99
   PubMed Web of Science ®Google Scholar
• Zhou ZL, Li X, Peng HY, et al. Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia. Acta Pharmacol Sin 2006;27(3):381-6
   PubMed Web of Science ®Google Scholar
• Conley R, Gupta SK, Sathyan G. Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form. Curr Med Res Opin 2006;22(10):1879-92
   PubMed Web of Science ®Google Scholar
• Ueng KC, Chen ZC, Yeh PS, et al. Nifedipine OROS in Chinese patients with hypertension--results of a post-marketing surveillance study in Taiwan. Blood Press Suppl 2005;1:32-8
   PubMedGoogle Scholar
• Chung M, Kourides I, Canovatchel W, et al. Pharmacokinetics and pharmacodynamics of extended-release glipizide GITS compared with immediate-release glipizide in patients with type II diabetes mellitus. J Clin Pharmacol 2002;42(6):651-7
   PubMed Web of Science ®Google Scholar
• Anderson RU, Mobley D, Blank B, et al. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group. J Urol 1999;161(6):1809-12
   PubMed Web of Science ®Google Scholar
• Chung M, Vashi V, Puente J, et al. Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation. Br J Clin Pharmacol 1999;48(5):678-87
   PubMed Web of Science ®Google Scholar
• Bass DM, Prevo M, Waxman DS. Gastrointestinal safety of an extended-release, nondeformable, oral dosage form OROS: a retrospective study. Drug Saf 2002;25(14):1021-33
   PubMed Web of Science ®Google Scholar
• Lecaillon JB, Massias P, Schoeller JP, et al. Influence of food on the absorption of metoprolol administered as an Oros drug delivery system to man. Br J Clin Pharmacol 1985;19 (Suppl 2):245S-249S
   Google Scholar
• Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000;157(4):514-20
   PubMed Web of Science ®Google Scholar
• Ereshefsky L, Mascarenas CA. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J Clin Psychiatry 2003;64(Suppl 16):18-23
   PubMed Web of Science ®Google Scholar
• Arakawa R, Ito H, Takano A, et al. Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. Psychopharmacology (Berl) 2008;197(2):229-35
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Bobo WV, Nuamah IF, et al. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. J Clin Psychiatry 2008;69(5):817-29
   PubMed Web of Science ®Google Scholar
• Schooler N, Gharabawi G, Bossie F. A “virtual” comparison of paliperidone ER and oral risperidone in patients with schizophrenia. Poster presented at 45th Annual Meeting of the American College of Neuropsychopharmacology; December 3-7, 2006; Hollywood
   Google Scholar
• Agid O, Kapur S, Arenovich T, et al. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry 2003;60(12):1228-35
   PubMed Web of Science ®Google Scholar
• Leucht S, Busch R, Hamann J, et al. Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol Psychiatry 2005;57(12):1543-9
   PubMed Web of Science ®Google Scholar
• Tzimos A, Samokhvalov V, Kramer M, et al. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension. Am J Geriatr Psychiatry 2008;16(1):31-43
   PubMed Web of Science ®Google Scholar
• ADA. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004;65:267-72
   PubMed Web of Science ®Google Scholar
• Matsui-sakata A, Ohtani H, Sawada Y. Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus. Drug Metab Pharmacokinet 2005;20(5):368-78
   PubMedGoogle Scholar
• Baptista T, Zárate J, Joober R, et al. Drug induced weight gain, an impediment to successful pharmacotherapy: focus on antipsychotics. Curr Drug Targets 2004;5(3):279-99
   PubMed Web of Science ®Google Scholar
• Buckley NA, Sanders P. Cardiovascular adverse effects of antipsychotic drugs. Drug Saf 2000;23(3):215-28
   PubMed Web of Science ®Google Scholar
• Luthringer R, Staner L, Noel N, et al. A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia. Int Clin Psychopharmacol 2007;22(5):299-308
   PubMed Web of Science ®Google Scholar
• Miller DD. Atypical antipsychotics: sleep, sedation, and efficacy. Prim Care Companion J Clin Psychiatry 2004;6 (Suppl 2):3-7
   Google Scholar
• Lane HY, Liu YC, Huang CL, et al. Risperidone-related weight gain: genetic and nongenetic predictors. J Clin Psychopharmacol 2006;26(2):128-34
   PubMed Web of Science ®Google Scholar
• Ellingrod VL, Miller D, Schultz SK, et al. CYP2D6 polymorphisms and atypical antipsychotic weight gain. Psychiatr Genet 2002;12(1):55-8
   PubMed Web of Science ®Google Scholar
• Llerena A, Berecz R, Dorado P, et al. QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations. J Psychopharmacol 2004;18(2):189-93
   PubMed Web of Science ®Google Scholar
• Kapur S, Langlois X, Vinken P, et al. The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J Pharmacol Exp Ther 2002;302(3):1129-34
   PubMed Web of Science ®Google Scholar
• Aravagiri M, Yuwiler A, Marder SR. Distribution after repeated oral administration of different dose levels of risperidone and 9-hydroxy-risperidone in the brain and other tissues of rat. Psychopharmacology (Berl) 1998;139(4):356-63
   PubMed Web of Science ®Google Scholar
• Melkersson KI. Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite. Hum Psychopharmacol 2006;21(8):529-32
   PubMed Web of Science ®Google Scholar
• Wang L, Yu L, Zhang AP, et al. Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia. J Psychopharmacol 2007;21(8):837-42
   PubMed Web of Science ®Google Scholar
• Kleinberg DL, Davis JM, de Coster R, et al. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 1999;19(1):57-61
   PubMed Web of Science ®Google Scholar
• Addington J, Addington D. Neurocognitive and social functioning in schizophrenia: a 2.5 year follow-up study. Schizophr Res 2000;44(1):47-56
   PubMed Web of Science ®Google Scholar
• Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996;153(3):321-30
   Google Scholar
• Matsui M, Sumiyoshi T, Arai H, et al. Cognitive functioning related to quality of life in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2008;32(1):280-7
   PubMed Web of Science ®Google Scholar
• Savilla K, Kettler L, Galletly C. Relationships between cognitive deficits, symptoms and quality of life in schizophrenia. Aust N Z J Psychiatry 2008;42(6):496-504
   PubMed Web of Science ®Google Scholar
• Kim SW, Shin IS, Kim JM, et al. Association between attitude toward medication and neurocognitive function in schizophrenia. Clin Neuropharmacol 2006;29(4):197-205
   PubMed Web of Science ®Google Scholar
• Lambert M, Naber D. Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life. CNS Drugs 2004;18 (Suppl 2):5-17
   Google Scholar
• Harvey PD, Patterson TL, Potter LS, et al. Improvement in social competence with short-term atypical antipsychotic treatment: a randomized, double-blind comparison of quetiapine versus risperidone for social competence, social cognition, and neuropsychological functioning. Am J Psychiatry 2006;163(11):1918-25
   PubMed Web of Science ®Google Scholar
• Gefvert O, Bergström M, Långström B, et al. Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. Psychopharmacology (Berl) 1998;135(2):119-26
   PubMed Web of Science ®Google Scholar
• Takano A, Suhara T, Kusumi I, et al. Time course of dopamine D2 receptor occupancy by clozapine with medium and high plasma concentrations. Prog Neuropsychopharmacol Biol Psychiatry 2006;30(1):75-81
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Rabinowitz J, Kemmler G, et al. Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year. Br J Psychiatry 2005;187:131-6
   PubMed Web of Science ®Google Scholar
• Kahn RS, Schulz SC, Palazov VD, et al. Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007;68(6):832-42
   PubMed Web of Science ®Google Scholar
• Mamo D, Kapur S, Keshavan M, et al. D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia. Neuropsychopharmacology 2008;33(2):298-304
   PubMed Web of Science ®Google Scholar